Prognostic Outcomes by Axillary Approach in Lobular and Ductal Breast Cancer With Sentinel Node Macrometastases: A Retrospective Cohort Study.

IF 2.5 3区 医学 Q2 ONCOLOGY
Amparo Garcia-Tejedor, Carla Julià, Julia Ciria, Rodrigo Guevara-Peralta, Carlos Ortega-Expósito, Raul Ortega, Agostina Stradella, Héctor Pérez-Montero, Gabriel Reyes-Juncan, Ana Benitez, Anna Guma, Juan Azcarate, Miriam Campos, Maria J Plà, Evelyn Martinez, Sonia Pernas, Jordi Ponce, Catalina Falo
{"title":"Prognostic Outcomes by Axillary Approach in Lobular and Ductal Breast Cancer With Sentinel Node Macrometastases: A Retrospective Cohort Study.","authors":"Amparo Garcia-Tejedor, Carla Julià, Julia Ciria, Rodrigo Guevara-Peralta, Carlos Ortega-Expósito, Raul Ortega, Agostina Stradella, Héctor Pérez-Montero, Gabriel Reyes-Juncan, Ana Benitez, Anna Guma, Juan Azcarate, Miriam Campos, Maria J Plà, Evelyn Martinez, Sonia Pernas, Jordi Ponce, Catalina Falo","doi":"10.1016/j.clbc.2025.07.022","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare survival outcomes between patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma non-special type (NST) presenting with sentinel lymph node biopsy (SLNB)-detected macrometastases in early-stage breast cancer.</p><p><strong>Materials and methods: </strong>A retrospective cohort study was conducted including 364 cN0 breast cancer patients with SLNB-detected macrometastases who underwent surgical treatment between July 2011 and December 2023. Patients were categorized as NST (n = 250) or ILC (n = 108). SLNB was the primary axillary staging procedure, with axillary lymph node dissection (ALND) performed according to predefined clinical criteria. Univariate and multivariate Cox regression analyses were used to identify predictors of pN2-pN3. Survival outcomes were assessed using Kaplan-Meier curves and compared with log-rank tests.</p><p><strong>Results: </strong>ILC patients presented with larger tumors, higher rates of multifocality, and greater axillary nodal involvement compared to NST. Surgery was more frequently mastectomy and ALND. pN2-N3 was identified in 12% of cases, with pT3 stage, ILC histology, and lymphovascular invasion as independent predictors. After a median follow-up of 7.6 years, the ILC group exhibited higher overall mortality (19.4% vs. 9.6%) and deaths attributed to systemic progression (57% vs. 29%). Ten-year distant disease-free survival and breast cancer-specific survival were significantly lower in the ILC cohort (63% vs. 87% and 65% vs. 93%, respectively; P < .05). Although 10-year overall survival was lower in ILC (54% vs. 79%), statistical significance was only observed in patients with advanced nodal disease (pN2-N3).</p><p><strong>Conclusions: </strong>ILC is associated with more advanced axillary burden and significantly worse long-term oncologic outcomes compared to NST carcinoma when macrometastases are present at SLNB.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.07.022","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To compare survival outcomes between patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma non-special type (NST) presenting with sentinel lymph node biopsy (SLNB)-detected macrometastases in early-stage breast cancer.

Materials and methods: A retrospective cohort study was conducted including 364 cN0 breast cancer patients with SLNB-detected macrometastases who underwent surgical treatment between July 2011 and December 2023. Patients were categorized as NST (n = 250) or ILC (n = 108). SLNB was the primary axillary staging procedure, with axillary lymph node dissection (ALND) performed according to predefined clinical criteria. Univariate and multivariate Cox regression analyses were used to identify predictors of pN2-pN3. Survival outcomes were assessed using Kaplan-Meier curves and compared with log-rank tests.

Results: ILC patients presented with larger tumors, higher rates of multifocality, and greater axillary nodal involvement compared to NST. Surgery was more frequently mastectomy and ALND. pN2-N3 was identified in 12% of cases, with pT3 stage, ILC histology, and lymphovascular invasion as independent predictors. After a median follow-up of 7.6 years, the ILC group exhibited higher overall mortality (19.4% vs. 9.6%) and deaths attributed to systemic progression (57% vs. 29%). Ten-year distant disease-free survival and breast cancer-specific survival were significantly lower in the ILC cohort (63% vs. 87% and 65% vs. 93%, respectively; P < .05). Although 10-year overall survival was lower in ILC (54% vs. 79%), statistical significance was only observed in patients with advanced nodal disease (pN2-N3).

Conclusions: ILC is associated with more advanced axillary burden and significantly worse long-term oncologic outcomes compared to NST carcinoma when macrometastases are present at SLNB.

腋窝入路治疗前哨淋巴结大转移的小叶和导管乳腺癌的预后:一项回顾性队列研究。
目的:比较浸润性小叶癌(ILC)和浸润性导管癌(NST)患者在早期乳腺癌中前哨淋巴结活检(SLNB)检测到的大转移的生存结果。材料与方法:对2011年7月至2023年12月接受手术治疗的364例cN0乳腺癌slnb大转移灶患者进行回顾性队列研究。患者分为NST组(n = 250)和ILC组(n = 108)。SLNB是主要的腋窝分期程序,根据预先确定的临床标准进行腋窝淋巴结清扫(ALND)。采用单因素和多因素Cox回归分析确定pN2-pN3的预测因子。生存结果采用Kaplan-Meier曲线进行评估,并与log-rank检验进行比较。结果:与NST相比,ILC患者表现为更大的肿瘤,更高的多发灶率和更大的腋窝淋巴结受累。手术更常见的是乳房切除术和ALND。12%的病例中发现pN2-N3, pT3分期、ILC组织学和淋巴血管侵袭是独立的预测因素。在中位随访7.6年后,ILC组表现出更高的总死亡率(19.4%对9.6%)和归因于全身进展的死亡率(57%对29%)。ILC组的10年远期无病生存率和乳腺癌特异性生存率显著降低(分别为63%对87%和65%对93%,P < 0.05)。尽管ILC患者的10年总生存率较低(54%对79%),但仅在晚期淋巴结疾病(pN2-N3)患者中观察到统计学意义。结论:与NST癌相比,当SLNB存在巨转移时,ILC与更晚期的腋窝负担相关,且长期肿瘤预后明显更差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical breast cancer
Clinical breast cancer 医学-肿瘤学
CiteScore
5.40
自引率
3.20%
发文量
174
审稿时长
48 days
期刊介绍: Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信